The combination of genomics and bioinformatics expertise now needed for target validation has led drugmakers to look outside their walls for skills, with Pfizer teaming with the Broad Institute on such a project. Now GlaxoSmithKline has set up its own initiative and called for its Big Pharma peers to get involved.
Translating all the information from the genomics revolution into verifiable drug targets has proven to be no easy task. Now, in an effort to bend the curve toward R&D success, GlaxoSmithKline is teaming up with external experts, putting up money and brainpower to launch a collaborative research effort.
The U.K.'s Wellcome Trust is putting up about $4.1 million to fund a collaboration between CRO Selcia and Edinburgh University, under which the two will develop new treatments for sleeping sickness.
With the help of Syncona, the Wellcome Trust's venture arm, Oxford University spinout NightstaRx has $20 million and a plan to develop gene therapies for degenarative eye conditions.
The falling cost of sequencing has created a new problem for research institutions--where to put all the data. At the Wellcome Trust Sanger Institute, 30 DNA sequencers generate a terabyte a day, meaning its 22 petabytes of storage is filling up. The time for a rethink on how it stores data has arrived.
Johnson & Johnson's Janssen is partnering with the University of Leuven in Belgium and the U.K.'s Wellcome Trust in an effort to combat the world's fastest-spreading tropical disease, dengue fever.
Johnson & Johnson ($JNJ) aims to advance antiviral compounds against the rising threat of dengue infection by teaming with Belgian academics whose backing from the Wellcome Trust has aided the discovery of potential drugs against all four strains of the mosquito-borne illness.
The U.K.'s largest charity has already begun to pour some serious pounds into biotech startups. The Wellcome Trust has organized its efforts under a new venture unit called Syncona to back early-stage outfits in biotech and other healthcare sectors with an initial £200 million ($325 million) fund.
London-based Cell Medica is coming to America. The cell therapy developer says it has pieced together a $26.5 million round to finance new operations in Texas to work on a cancer immunotherapy program.
Edmond de Rothschild Investment Partners, a high-profile venture player in the European life sciences scene, has braved a tough financial environment and rounded up a bit more than $152 million for its fourth biotech fund.